NASDAQ
TNXP
Last Price
US $12.34
KEY FIGURES
MKT CAP
$210.7M
EPS
TTM
$-10.75
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
16.08x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-67.65%
Return on equity
ROIC: -66.19%
Valuation History
-0.90X
Price to Earnings
EV/EBITDA: -0.18X
Cash flow
Profit margin
-
(FY vs FY)
EBITDA Y/Y
-16.19%
(FY vs FY)
Cash flow Y/Y
-11.16%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $12.34
—
Default assumptions
EBITDA Multiple
Fair Value
Market $12.34
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Tonix Pharmaceuticals Holding Corp. cash flow to debt ratio of -7.63K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Tonix Pharmaceuticals Holding Corp.'s free cash flow has decreased 69.08% from $-61.05M last year to $-103.21M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Tonix Pharmaceuticals Holding Corp.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Tonix Pharmaceuticals Holding Corp.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.01 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Tonix Pharmaceuticals Holding Corp. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Tonix Pharmaceuticals Holding Corp. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Tonix Pharmaceuticals Holding Corp.'s profit margin has increased (-34.83%) in the last year from -1.29K% to -839.52%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Tonix Pharmaceuticals Holding Corp.'s short-term assets of $228.88M exceed its short-term liabilities of $30.84M
Decreasing performance - ROA.
Tonix Pharmaceuticals Holding Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Tonix Pharmaceuticals Holding Corp.'s return on equity of -67.65%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Tonix Pharmaceuticals Holding Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Tonix Pharmaceuticals Holding Corp. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Tonix Pharmaceuticals Holding Corp. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Tonix Pharmaceuticals Holding Corp. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Tonix Pharmaceuticals Holding Corp.'s yearly earnings has increased -4.63% since last year from $-130.04M to $-124.02M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Tonix Pharmaceuticals Holding Corp.'s yearly revenue has increased 29.85% since last year from $10.09M to $13.11M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -66.19% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Tonix Pharmaceuticals Holding Corp. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Tonix Pharmaceuticals Holding Corp. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Tonix Pharmaceuticals Holding Corp. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Tonix Pharmaceuticals Holding Corp. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Tonix Pharmaceuticals Holding Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Tonix Pharmaceuticals Holding Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Tonix Pharmaceuticals Holding Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Tonix Pharmaceuticals Holding Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Tonix Pharmaceuticals Holding Corp. has a price-to-book ratio of 0.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Tonix Pharmaceuticals Holding Corp. has a price-to-sales ratio of 12.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue